NCT03396926 - Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions

Microsatellite StableMismatch Repair Protein ProficientStage III Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given intravenously (IV)

DRUG

Capecitabine

Given orally (PO)

PROCEDURE

Specimen collection

For use in correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER